The association between statin and COVID-19 adverse outcomes: National COVID-19 cohort in South Korea

Ronald Chow, Jihui Lee, Hyerim Noh, Jongseong Lee, Hyun Joon Shin, Young‐Geun ChoimedRxiv 2021 · DOI

Abstract

There currently exists limited and conflicting clinical data on the use of statins amongst COVID-19 patients. This study aimed to compare hospitalized patients with COVID-19 who did and did not receive statins in terms of clinical outcomes. Using a population-based retrospective cohort from South Korea’s nationwide healthcare database (n=4,349), we analyzed the association between prior statin use and a composite endpoint of all-cause death, ICU admission, mechanical ventilation, and cardiovascular outcomes. While the primary analysis showed no significant difference in outcomes for the general population (IPTW OR 0.82; 95% CI: 0.60–1.11), a significant protective effect was observed in patients with hypertension (IPTW OR 0.40; 95% CI: 0.23–0.69). These findings suggest that statins are safe for COVID-19 patients and may offer specific benefits to those with underlying hypertension.

Introduction

Early in the COVID-19 pandemic, the medical community faced uncertainty regarding the impact of common medications on disease severity. Statins, widely prescribed for hyperlipidemia, were a particular subject of debate. On one hand, their anti-inflammatory and immunomodulatory properties suggested a potential to dampen the "cytokine storm" associated with severe COVID-19. On the other hand, concerns were raised that statins might upregulate ACE2—the receptor used by SARS-CoV-2 for cell entry—potentially exacerbating the infection.

Given the lack of consensus, clinical guidelines generally recommended continuing statin therapy in patients already receiving it. This study sought to provide real-world evidence from a large national cohort to clarify whether pre-existing statin use influences COVID-19 outcomes.

Methods

Data Sources and Study Population

The researchers utilized two primary nationwide databases from South Korea: the Health Insurance Review and Assessment Service (HIRA), which covers approximately 98% of the population, and the Korean Disease Control and Prevention Agency (KDCA), which provided confirmed COVID-19 test results and mortality data.

The study identified 4,349 patients aged 40 years or older who were hospitalized with COVID-19 as of May 15, 2020. "Statin users" (n=1,115) were defined as individuals with inpatient or outpatient prescriptions for statins within the 240 days prior to hospitalization. "Non-users" (n=3,234) had no such records during that period.

Statistical Analysis

To account for the inherent differences between statin users (who were generally older and had more comorbidities) and non-users, the study employed Inverse Probability of Treatment Weighting (IPTW). This technique uses propensity scores to balance the two groups across 20 different comorbidities and 12 co-medications, effectively creating a balanced "pseudo-population" for comparison. The primary outcome was a composite endpoint including all-cause death, ICU admission, mechanical ventilation, and major cardiovascular events (MI, TIA, or stroke).

Results

Primary Outcomes

In the IPTW-adjusted analysis, statin use was not associated with an increased risk of the primary composite outcome. The adjusted Odds Ratio (OR) was 0.82 (95% CI: 0.60–1.11). While this indicates a trend toward protection, it did not reach statistical significance for the general cohort. However, this "neutral" result is clinically significant as it confirms that prior statin use does not worsen COVID-19 severity.

Subgroup Analysis: The Hypertension Effect

A striking finding emerged during subgroup analysis. For patients with a history of hypertension, statin use was associated with a significant reduction in adverse outcomes, with an OR of 0.40 (95% CI: 0.23–0.69). The p-value for interaction (0.0087) confirmed that hypertension significantly modified the effect of statins on COVID-19 outcomes.

Sensitivity Analyses

When the researchers applied alternative statistical models, such as Propensity Score matching or SMR weighting, the results frequently shifted toward a more pronounced protective effect for all-cause death across the entire cohort. This suggests that the primary IPTW model may have been a conservative estimate of the potential benefits of statins.

Discussion

The findings support the safety of statins in the context of COVID-19 and suggest a potential therapeutic benefit, particularly in hypertensive populations. Several biological mechanisms may explain these observations:

  1. Inflammation Modulation: Statins may stabilize the MYD88 protein, thereby reducing the inflammatory response.
  2. ACE2 Regulation: While the virus downregulates ACE2 (leading to vascular and lung injury), statins may counter this effect, protecting the vascular system.
  3. Endothelial Protection: Statins are known to improve endothelial function, which is often severely compromised in COVID-19 patients.

Limitations

The study is limited by its retrospective nature and reliance on administrative claims data. The researchers could not verify medication adherence (whether patients actually took the prescribed statins) or access granular clinical data such as BMI, actual blood pressure readings, or LDL cholesterol levels. Additionally, minor cardiovascular events like TIA might be underreported in claims databases.

Conclusion

This national cohort study provides evidence that pre-existing statin use is not detrimental to COVID-19 patients and may significantly improve outcomes for those with hypertension. Given that statins are widely available, inexpensive, and have a well-established safety profile, they warrant further investigation in prospective clinical trials as a potential tool in the management of COVID-19.

Summary updated

Abstract

Summary Background There currently exists limited and conflicting clinical data on the use of statins amongst COVID-19 patients. Given the both paucity and lack of consensus among data on statin’s efficacy and safety amongst COVID-19 patients, the current guideline is to continue statin in COVID-19 patients, who have previously been treated with statins. The aim of this paper was to compare hospitalized patients with COVID-19 who did and did not receive statins, in terms of COVID-19 outcomes. Methods We conducted population-based retrospective study using South Korea’s nationwide healthcare database as of May 15 2020. We identified 4,349 patients hospitalized with COVID-19 and aged 40 years or older. The cohort entry was defined as the date of hospitalization. Statin users were individuals with inpatient and outpatient prescription records of statins in the 240 days before cohort entry, and non-users were those without such records during this period. Our primary outcome was a composite endpoint of all-cause death, intensive care unit (ICU) admission, mechanical ventilation use and cardiovascular outcomes (myocardial infarction (MI), transient cerebral ischemic attacks (TIA) or stroke). We conducted inverse probability of treatment weighting (IPTW)-adjusted logistic regression analysis to estimate odds ratio (OR) and corresponding 95% confidence intervals (CI), to compare outcomes between statin users and non-users. Findings 1,115 patients were statin users (mean age = 65.9 years; 60% female), and 3,234 were non-users (mean age = 58.3 years; 64% female). Statin use was not associated with increased risk of the primary outcome (IPTW OR 0.82; 95% CI: 0.60-1.11). Subgroup analysis showed a protective role of statins, for individuals with hypertension (IPTW OR 0.40; 95% CI: 0.23-0.69, p for interaction: 0.0087). Interpretation Given that statins are not detrimental and that it may be beneficial amongst hypertensive patients and relatively cheap, we would encourage further investigation into statin for the prevention and treatment of COVID-19. Funding YGC’s work was partially supported by 2020R1G1A1A01006229 awarded by the National Research Foundation of Korea. Research in context Evidence before this study There is limited and conflicting data reporting on statin use among COVID-19 patients, and its association with COVID-19 outcomes Added value of this study We report no difference in COVID-19 outcomes between patients who used and did not use statins prior to COVID-19 diagnosis, except in hypertensive patients in which statins was shown to have a protective effect. Implications of all the available evidence As statins are not detrimental and relatively cheap, we encourage further investigation into statin for the prevention and treatment of COVID-19.
BibTeX
@misc{chow2021association,
  author = {Ronald Chow and Jihui Lee and Hyerim Noh and Jongseong Lee and Hyun Joon Shin and Young‐Geun Choi},
  title = {{The association between statin and COVID-19 adverse outcomes: National COVID-19 cohort in South Korea}},
  year = {2021},
  doi = {10.1101/2021.07.30.21261329},
  howpublished = {medRxiv},
}
Figure